E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
With the FDA approval, Haisco’s Cipepofol becomes the first China-originated innovative intravenous anesthetic to enter the global market.
imphoenix82
India’s healthcare, pharmaceutical, and medical device industries are set for another dynamic year in 2026, with several major conferences, expos, and summits taking place across the country.
imphoenix82
The revised sampling guidelines mandate that every Drugs Inspector collect at least 10 samples per month.
dineshwori
If approved, Zydus Therapeutics plans to launch saroglitazar in the United States in Q4 of FY 27.
imphoenix82
Unlike many existing treatments for fatty liver disease that mainly focus on weight loss, this new experimental drug targets the disease process itself.
imphoenix82
WHO advisory groups recommend prioritizing three candidate therapeutics for Bundibugyo Ebola trials: Mapp Biopharmaceutical’s MBP134, Regeneron’s Maftivimab, and Gilead Sciences’ antiviral remdesivir.
imphoenix82
While medications remain the first-line treatment for trigeminal neuralgia, CyberKnife-based stereotactic radiosurgery can offer significant relief when conventional therapies fail.
imphoenix82
Biohub’s world model brings together open-source AI models — ESMC, ESMFold2, and ESM Atlas — to help researchers better understand proteins and speed up the discovery of new therapeutics.
imphoenix82
The global CAR T-cell therapy market is projected to grow from USD 6.78 billion in 2026 to USD 13.56 billion by 2031.
dineshwori
The purchase of the three vaccine developers could cost Lilly up to USD 3.8 billion.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
